PATIENT-PROFILED TREATMENT RESPONSES AND CARDIAC ENDPOINT PREVENTION IN THE VALUE OUTCOME TRIAL

作者：Peter W. de Leeuw, Camilla L. Søraas, K JAMERSON, G Mancia, Maria H. Mehlum, Kjeldsen Se, Michael A. Weber · 发表于：Journal of Hypertension · 年份：2026 · DOI：10.1097/01.hjh.0001197256.41618.b6 · 研究领域：Blood Pressure and Hypertension Studies、Heart rate and cardiovascular health、Medication Adherence and Compliance

Objective: Although many hypertension outcome trials have shown the benefit of treating hypertensive patients, subgroup analyses to explore the effects of treatment in relation to certain patient characteristics are limited. Whenever subgroup analyses of major hypertension trials are available, these are usually based on one factor at the time and not on a more comprehensive patient profile. We hypothesized that blood pressure (BP) responses and cardiovascular events differ significantly between patient profiles that are constructed by a combination of individual predictors. Design and method: To test our hypothesis, we reanalysed the data from the double-blinded VALUE-outcome trial (n=15.313) and randomly divided the patient population (2:1) into an exploration and a validation cohort. We constructed composite patient profiles based on the combination of four proven predictors of BP control (age, severity of hypertension, comorbidity and previous treatment status). Next, we tested in the exploration cohort whether blood pressure control (BPC) after six months of therapy among these profiles differed from those in the entire patient group. We also determined to what extent the various profiles were related to primary cardiac events. Finally, we explored whether the results from the exploration cohort could be validated in the other cohort. Only profiles containing 50 or more patients were used. Results: Of the 121 profiles identified in the trial, 36 had enough patients for a...